Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Advanced Tumor Angiogenesis Research

Executive Summary: Anlotinib hydrochloride (CAS 1058157-76-8) is a small-molecule inhibitor targeting VEGFR2, PDGFRβ, and FGFR1, demonstrating nanomolar potency in anti-angiogenic assays (Chen & Feng 2019). It exhibits superior inhibition of endothelial cell migration and tube formation compared to sunitinib, sorafenib, and nintedanib under matched conditions. Pharmacokinetically, it offers high oral bioavailability and broad tissue distribution, including the ability to cross the blood-brain barrier. Safety profiles show high median lethal dose and minimal organ/genetic toxicity in preclinical models. APExBIO provides Anlotinib (hydrochloride) (SKU C8688) specifically for research workflows in cancer and angiogenesis studies.

Biological Rationale

Tumor angiogenesis is a hallmark of cancer progression, driven by signaling through vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) receptors. Inhibition of these pathways suppresses neovascularization essential for tumor growth and metastasis. Multi-target tyrosine kinase inhibitors (TKIs) offer a strategy to simultaneously block redundant pro-angiogenic signals. Anlotinib hydrochloride is designed to inhibit VEGFR2, PDGFRβ, and FGFR1 at nanomolar concentrations, addressing the complexity of angiogenic signaling in tumor microenvironments (Chen & Feng 2019). This broad activity profile positions anlotinib as a key tool for dissecting tyrosine kinase signaling pathway roles in cancer biology.

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib hydrochloride acts as a competitive inhibitor at the ATP-binding sites of VEGFR2 (IC₅₀ = 5.6 ± 1.2 nM), PDGFRβ (IC₅₀ = 8.7 ± 3.4 nM), and FGFR1 (IC₅₀ = 11.7 ± 4.1 nM) (APExBIO product page). By blocking receptor phosphorylation, anlotinib prevents downstream activation of ERK and MAPK signaling cascades. This leads to concentration-dependent inhibition of endothelial cell migration and capillary-like tube formation in vitro. Unlike single-target TKIs, anlotinib also suppresses c-Kit and MET receptor activity, broadening its anti-angiogenic and anti-tumor spectrum (Chen & Feng 2019). In cellular assays with human vascular endothelial cells (EA.hy 926), anlotinib consistently reduces VEGF/PDGF-BB/FGF-2-induced phenotypes.

Evidence & Benchmarks

• Anlotinib inhibits VEGFR2 phosphorylation in vitro with IC₅₀ = 5.6 ± 1.2 nM (phosphorylation/ELISA, pH 7.4, 25°C) (Chen & Feng 2019, Table 1).
• It achieves 93% plasma protein binding in human serum (ultrafiltration, 37°C) (APExBIO product docs).
• Bioavailability in rats ranges from 28% to 58% after oral dosing (5–20 mg/kg, fasted) (Chen & Feng 2019).
• High tissue accumulation in lung, liver, kidney, heart, and tumor observed post-administration (LC-MS/MS quantification) (Chen & Feng 2019, Figure 3).
• In vivo, anlotinib reduces tumor angiogenesis and growth in models of intra-abdominal desmoplastic small round cell tumor (IADSRCT) (case report, maintenance therapy, 38-year-old male) (Chen & Feng 2019).
• Compared to sunitinib, sorafenib, and nintedanib, anlotinib shows superior inhibition in capillary tube formation assays (matched dosing, 10–50 nM) (MOG35-55.com article).
• Median lethal dose (LD₅₀) in 14-day oral toxicity studies is 1735.9 mg/kg, indicating low acute toxicity (mouse model) (APExBIO docs).

This article updates and extends guidance found in "Anlotinib Hydrochloride: Applied Strategies for Tumor Ang...", by providing quantitative inter-assay benchmarks and a direct comparison to other TKIs. For advanced troubleshooting and experimental integration, see "Optimizing Lab Assays with Anlotinib (hydrochloride)", which focuses on practical protocol refinements. For a mechanistic review and translational outlook, "Harnessing Multi-Target Tyrosine Kinase Inhibition: Strat..." is complementary but less focused on quantitative comparison.

Applications, Limits & Misconceptions

Anlotinib (hydrochloride) is widely used in cancer research for dissecting angiogenic signaling, evaluating anti-angiogenic compounds, and modeling tumor microenvironment responses. It is recommended for in vitro cell migration, capillary tube formation, and ERK pathway modulation assays. Pharmacokinetic properties support in vivo use in rodent models. However, it is not approved for diagnostic, therapeutic, or clinical use; all applications must remain within research boundaries (APExBIO).

Common Pitfalls or Misconceptions

• Not a clinical therapeutic: Anlotinib supplied by APExBIO (C8688) is for research use only, not for human or veterinary treatment.
• Single-pathway inhibition is insufficient: It is ineffective if only one angiogenic pathway is active; simultaneous VEGFR/PDGFR/FGFR signaling is required for full effect.
• Cell line specificity: Efficacy and IC₅₀ values may differ in non-endothelial or non-tumor cell types.
• Solubility limits: Poor solubility in aqueous buffers above 100 μM may impact assay reproducibility.
• Species differences: Metabolism and tissue distribution in rodents may not fully predict human pharmacokinetics.

Workflow Integration & Parameters

For optimal results, Anlotinib (hydrochloride) should be reconstituted in DMSO to a stock concentration of 10 mM, then diluted into assay buffer (Optimizing Lab Assays with Anlotinib). In cell-based assays, concentrations from 1 nM to 50 nM enable dose-response curves for endothelial migration and tube formation (EA.hy 926 or HUVEC cells, 37°C, 5% CO₂). For in vivo studies, oral dosing in rodents typically ranges from 1 mg/kg to 10 mg/kg. Storage at -20°C is recommended for long-term stability. Minimal drug is excreted unchanged, so metabolite analysis may be required for pharmacokinetic studies. APExBIO's C8688 kit includes validated protocols and stability data to support reproducibility.

Conclusion & Outlook

Anlotinib hydrochloride represents a next-generation anti-angiogenic small molecule, validated for research use in dissecting tyrosine kinase signaling pathways. Its superior potency, broad target profile, and favorable pharmacokinetics make it the reagent of choice for advanced cancer and vascular biology studies. For detailed protocols and batch-tested product, researchers should refer to Anlotinib (hydrochloride) from APExBIO. Ongoing research is expected to expand its application into new tumor models and combinatorial assay systems.